Evidence map›Paper›PMID 38114390›Full record

ArticleClinical genitourinary cancer2024

Central Nervous System Disease Progression Among Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Case Series.

Chase Shipp, Tanya Jindal, Jonathan Chou, Terence W Friedlander, Vadim S Koshkin, Vipul Kumar

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical genitourinary cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chase ShippUniversity of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.
Tanya JindalUniversity of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.
Jonathan ChouUniversity of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.
Terence W FriedlanderUniversity of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.
Vadim S KoshkinUniversity of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA. Electronic address: Vadim.Koshkin@ucsf.edu.
Vipul KumarUniversity of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA. Electronic address: Vipul.Kumar@ucsf.edu.

Funding

Defining the roles of PPARgamma and TGFbeta in regulating NECTIN4 and resistance to NECTIN4-targeting therapiesK08CA273514 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jonathan Chou · 2022 to 2026
$1.3M
NCI NIH HHS K08 CA273514
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, Transitional CellUrinary Bladder NeoplasmsAntibodies, MonoclonalHumansAntibodies, Monoclonalenfortumab vedotin

Identifiers

PMID38114390
PMCPMC12172690

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.